Evidence map›Paper›PMID 37497216›Full record

ReviewFrontiers in immunology2023

E3 ubiquitin ligases and deubiquitinases in bladder cancer tumorigenesis and implications for immunotherapies.

Maoyu Wang, Zhensheng Zhang, Zhizhou Li, Yasheng Zhu, Chuanliang Xu

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Maoyu WangDepartment of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Zhensheng ZhangDepartment of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Zhizhou LiDepartment of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Yasheng ZhuDepartment of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Chuanliang XuDepartment of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Second Military Medical University · CNChanghai Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the rapidly increasing incidence of bladder cancer in China and worldwide, great efforts have been made to understand the detailed mechanism of bladder cancer tumorigenesis. Recently, the introduction of immune checkpoint inhibitor-based immunotherapy has changed the treatment strategy for bladder cancer, especially for advanced bladder cancer, and has improved the survival of patients. The ubiquitin-proteasome system, which affects many biological processes, plays an important role in bladder cancer. Several E3 ubiquitin ligases and deubiquitinases target immune checkpoints, either directly or indirectly. In this review, we summarize the recent progress in E3 ubiquitin ligases and deubiquitinases in bladder cancer tumorigenesis and further highlight the implications for bladder cancer immunotherapies.

Indexed as

Ubiquitin-Protein LigasesUrinary Bladder NeoplasmsCarcinogenesisCell Transformation, NeoplasticDeubiquitinating EnzymesHumansImmunotherapyUbiquitinDeubiquitinating EnzymesUbiquitinUbiquitin-Protein Ligasesbladder cancerdeubiquitinasesE3 ubiquitin ligaseimmunotherapytumorigenesis

Identifiers

PMID37497216
PMCPMC10366618
OpenAlexW4383955257

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.